CMS says companies that incorrectly classify drugs in Medicaid are liable for False Claims Act penalties, coming as Senate Judiciary leaders want the Justice Department to probe whether Mylan broke the law by misclassifying EpiPen as a generic. “Manufacturers that fail to accurately report product and pricing data to the rebate program and pay insufficient rebates may be subject to liability under the False Claims Act, a penalty of up to $100,000 per item of false information under the Rebate...